In breast cancer, low EphB6 expression is linked to enhanced tumor invasiveness; treatment of aggressive breast cancer cell lines with 5’-aza-2’-deoxycytidine elevates EphB6 expression and to reduces tumor cell invasiveness [48]. Here, EPHB6 is linked to neoplasm.